---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000612"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:06:35.742455+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics reports Q1 2022 net loss of $14.7M; cash at $265.8M

## Summary
- Net loss of $14.7M ($0.30 per share) vs. $12.7M in the prior quarter.
- Cash, equivalents and marketable securities of $265.8M; expected to fund operations through 2024.
- Completed enrollment of ARCH open-label study of EDG-5506 in BMD; Phase 2 trials planned for 2022.
- R&D expenses $11.1M, up $2.0M from prior quarter; G&A flat at $3.7M.
- Advanced preclinical EDG-002 program targeting hypertrophic cardiomyopathy; IND-enabling studies in 2022.

## SEC filing metadata
- accession: 0001157523-22-000612
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752322000612/0001157523-22-000612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752322000612/a52714442.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000612
- JSON: https://secwatch.observer/filing/0001157523-22-000612.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000612.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.